Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Yposkesi
Yposkesi
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Manufacturing
SK pharmteco subsidiary Yposkesi launches AAVelocity, a plug-and-play AAV platform
Designed to shorten turnaround on manufacturing AAVs, this new platform offers CGT developers more flexibility when producing viral vectors for clinical and commercial use
Ingredients
Yposkesi launches lentiviral vector production platform optimised for higher yields
Yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing arm for cell and gene therapies, has launched LentiSure
Research & Development
Yposkesi joins BioPhorum CGT consortium
Key challenges facing biopharmaceutical manufacturers include ensuring production efficiency while operating in a rapidly evolving regulatory environment
Finance
Yposkesi begins construction of second bioproduction site
Backed by majority shareholder SK Pharmteco, Yposkesi is investing $71m in the 5,000 sqm facility. The construction is projected to create approximately 80 jobs by 2023
Manufacturing
Axovant Gene Therapies chooses Yposkesi for viral vector production
The initial focus of the agreement will be on AAV-based gene therapies
Pharmaceutical
Yposkesi appoints Dr Fraser Wright as Senior Advisor
Subscribe now